Monte Rosa Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Monte Rosa Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 346.71K shares.
- Monte Rosa Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 574.84K shares, a 24103.75% increase year-over-year.
- Monte Rosa Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 703.85K shares, a 1055.40% increase year-over-year.
- Monte Rosa Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 72.89K shares, a 2300.86% increase year-over-year.
- Monte Rosa Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 779.11K shares, a 160.38% increase from fiscal 2024.
- Monte Rosa Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 299.22K shares, a 46.75% decline from fiscal 2023.
- Monte Rosa Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 561.90K shares, a 378.01% increase from fiscal 2022.
- Monte Rosa Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 117.55K shares, a 30.06% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 346.71K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 1.70M shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 574.84K shares 10-Q · filed 2026-05-07 | 1.35M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 703.85K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 779.11K shares 10-K · filed 2026-03-17 |
| 2025-09-30 | 72.89K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 136.18K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 66.33K shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 2.38K shares 10-Q · filed 2025-05-08 | 256.49K shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 60.92K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | 299.22K shares 10-K · filed 2025-03-20 |
| 2024-09-30 | 3.04K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 250.70K shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 190.16K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 645.58K shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 45.11K shares 10-Q · filed 2024-05-09 | 602.75K shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 12.40K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | 561.90K shares 10-K · filed 2024-03-14 |
| 2023-09-30 | 397.91K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 571.33K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 147.33K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 189.47K shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 4.26K shares 10-Q · filed 2023-05-11 | 61.57K shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 21.83K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | 117.55K shares 10-K · filed 2023-03-16 |
| 2022-09-30 | 16.05K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 109.16K shares derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | 19.44K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 93.11K shares derived: sum of 4 quarters · filed 2022-08-11 |
| 2022-03-31 | 60.24K shares 10-Q · filed 2022-05-11 | |
| 2021-12-31 | 13.43K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | 90.38K shares 10-K · filed 2022-03-29 |
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |